Cassava Sciences (SAVA) Announces Positive Top-Line Clinical Results in Phase 2 Study Evaluating Simufilam in Alzheimer’s Disease
Go back to Cassava Sciences (SAVA) Announces Positive Top-Line Clinical Results in Phase 2 Study Evaluating Simufilam in Alzheimer’s Disease(NASDAQ: SAVA) | Delayed: 20.42 --0 (-0%) | |||||
---|---|---|---|---|---|---|
Previous Close | $20.42 | 52 Week High | $ | |||
Open | $20.42 | 52 Week Low | $ | |||
Day High | $20.42 | P/E | N/A | |||
Day Low | $20.42 | EPS | $ | |||
Volume | 6 |